期刊
NEURO-ONCOLOGY
卷 17, 期 2, 页码 189-199出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/nou164
关键词
glioblastoma; meningioma; mTORC1; mTORC2
资金
- Deutsche Krebshilfe [108987]
- Wilhelm Sander-Stiftung [2010.017.1, 2010.017.2]
- Deutsche Kinderkrebsstiftung [DKS 2013.04]
Inhibition of the mammalian target of rapamycin (mTOR) signaling pathway has become an attractive target for human cancer therapy. Hyperactivation of mTOR has been reported in both sporadic and syndromic (hereditary) brain tumors. In contrast to the large number of successful clinical trials employing mTOR inhibitors in different types of epithelial neoplasms, their use to treat intracranial neoplasms is more limited. In this review, we summarize the role of mTOR activation in brain tumor pathogenesis and growth relevant to new human brain tumor trials currently under way using mTOR inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据